+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID06985355

Evaluation of MHB046C Injection for Safety, Tolerability, Pharmacokinetics, and Efficacy in Patients With Advanced Solid Tumors

Led by Minghui Pharmaceutical (Hangzhou) Ltd · Updated on 2026-10-09

200

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating MHB046C, a drug being studied in a first-in-human, open-label, multicenter Phase III trial for patients with advanced solid tumors. The study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of MHB046C monotherapy, including determining the maximum tolerated dose. This trial involves adults with advanced solid cancers that have not responded to or are intolerant of standard treatments, or have no standard options available. The trial consists of two parts a dose escalation phase followed by an indication expansion phase. In the dose escalation phase, patients receive intravenous MHB046C every three weeks in six escalating dose cohorts to evaluate safety and identify the recommended dose. The indication expansion phase further explores safety and efficacy of MHB046C monotherapy in specific advanced solid tumor types using doses determined in the earlier phase. Treatment continues until unacceptable toxicity or disease progression occurs. Participants will be monitored with assessments including tumor response evaluations by RECIST v1.1, adverse event tracking, and pharmacokinetic testing from before dosing up to several years. Outcome measures include maximum tolerated dose, overall response rate, duration of response, disease control rate, progression-free survival, and overall survival over up to five years. Safety monitoring also includes immunogenicity and long-term follow-up. Participants remain under study care until progression, withdrawal, or loss to follow-up.

CONDITIONS

Brief Title

A Study of MHB046C Injection in Patients With Advanced Solid Tumors

Research Team

V

VP of R&D

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here